Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
News|Articles|September 2, 2001
- Pharmaceutical Technology-09-02-2001
- Volume 25
- Issue 9
Six Sigma Can Give Contractors a Quality Advantage
Author(s)Jim Miller
This projectbased qualityimprovement program uses shortterm goals to achieve the longterm objectives of constant, continuous improvement.
Advertisement
Articles in this issue
about 25 years ago
Industry Changes OTC Labels as Deadline Approachesabout 25 years ago
A Report of the PQRI Workshop on Blend Uniformityabout 25 years ago
Are You Ready for Global Manufacturing?about 25 years ago
Pharmaceutical Coverage and Costsabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5